Vous êtes ici: Home > Therapeutics (ancienne) > Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis

J Cannabis Ther 2002(1):003-57

Chronic Medical Cannabis Use

Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis

Author
E. Russo, M.L. Mathre, A. Byrne, R. Velin, P.J. Bach, J. Sanchez-Ramos, K.A. Kirlin

Abstract
The Missoula Chronic Clinical Cannabis Use Study was proposed to investigate the therapeutic bepnefits and adverse effects of prolonged use of "medical marijuana" in a cohort of seriously ill patients. Use of cannabis was approved through the Compassionate Investigational New Drug (IND) program of the Food and Drug Administration (FDA). Cannabis is obtained from the National Institute on Drug Abuse (NIDA), and is utilized under the supervision of a study physician.

The aim of this study is to examine the overall health status of 4 of the 7 surviving patients in the program. This project provides the first opportunity to scrutinize the long-term effects of cannabis on patients who have used a known dosage of a standardized, heat-sterilized quality-controlled supply of low-grade marijuana for 11 to 27 years.

Results demonstrate clinical effectiveness in these patients in treating glaucoma, chronic musculoskeletal pain, spasm and nausea, and spasticity of multiple sclerosis. All 4 patients are stable with respect to their chronic conditions, and are taking many fewer standard pharmaceuticals than previously.

Mild changes in pulmonary function were observed in 2 patients, while no functionally significant attributable sequelae were noted in any other physiological system examined in the study, which included: MRI scans of the brain, pulmonary function tests, chest X-ray, neuropsychological tests, hormone and immunological assays, electroencephalography, P300 testing, history, and neurological clinical examination. These results would support the provision of clinical cannabis to a greater number of patients in need. We believe that cannabis can be a safe and effective medicine with various suggested improvements in the existing Compassionate IND program.


Keywords
Cannabis, medical marijuana, hashish, investigational new drug, compassionate use, NIDA, FDA, herbal medicine, analgesia, spasticity, chronic pain, glaucoma, multiple sclerosis, epidemiology, history of medicine, drug policy

Texte intégral au format PDF ]

Events Online Gratuits

Vous pouvez trouver toutes les informations ici.

L'IACM organise une série de webinaires gratuits et une réunion d'anniversaire en ligne gratuite d'octobre à décembre 2020.

Tous les webinaires se dérouleront en anglais et seront sous-titrés en allemand, français, espagnol et portugais. Tous les webinaires seront disponibles en ligne jusqu'en mars 2021.

La réunion en ligne pour célébrer le 20e anniversaire de l'IACM et pour honorer le 90e anniversaire de Raphael Mechoulam sera une session en direct seulement le 5 novembre 2020.

Les intervenants de la série de webinaires sont Donald I. Abrams, Bonni Goldstein, Franjo Grotenhermen, Manuel Guzmán, Raphael Mechoulam, Kirsten Müller-Vahl, Roger Pertwee, Daniele Piomelli et Ethan Russo.

Vous pouvez trouver toutes les informations ici.

 

IACM Conference 2021

La 12eme Conférence de l'IACM sur les cannabinoïdes en médecine se tiendra à Bâle, en Suisse, du 14 au 16 octobre 2021.

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.